Reviva prices $9M public offering of 27M shares and warrants at $0.335/unit

REVIVA PHARMACEUTICALS HOLDINGS, INC.

27M shares of common stock plus Series E (5-year term) and Series F (1-year term) warrants, each exercisable for 27M shares at $0.335.
Gross proceeds of $9M; net proceeds ~$8.1M after fees and expenses.
Offering expected to close on or about September 22, 2025, subject to customary conditions.
Proceeds to fund R&D activities and for working capital and general corporate purposes.
Placement agent: A.G.P./Alliance Global Partners; securities offered under effective shelf registration statement.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.